Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

Bibliography

• KEEN H, CLARK C, LAAKSO M: Reducing the burden of diabetes: managing cardiovascular disease. Diabetes Metab. Res. Rev. (1999) 15:186–196.
   PubMed Web of Science ®Google Scholar
• ••Insightful comments on the relationship between diabetesand macrovascular complications/cardiovascular disease. It supports the current recommendations for optimising care of patients with diabetes who are at significant risk for CHD.
   Google Scholar
• LIM SC, TAI ES, TAN BY, CHEW SK, TAN CE: Cardiovas-cular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care (2000) 23:278–282.
   PubMed Web of Science ®Google Scholar
• STERN MP: The effect of glycemic control on theincidence of macrovascular complications of Type 2 diabetes. Arch. Fam. Med. (1998) 7:155–162.
   PubMedGoogle Scholar
• •Practical commentary on identifying the benefits of aggres-sive glycaemic control as related to macrovascular disease.
   Google Scholar
• WILD SH, DUNN CJ, MCKEIGUE PM, COMTE S: Glycemic control and cardiovascular disease in type 2 diabetes: a review. Diabetes Metab. Res. Rev. (1999) 15:197–204.
   PubMed Web of Science ®Google Scholar
• •A useful summary to position the importance of glycaemic control relative to general risk reduction approaches in the management of type 2 diabetes.
   Google Scholar
• CLARK CM, FRADKIN JE, HISS RG, LORENZ RA, VINICOR F, WARREN-BOULTON E: Promoting early diagnosis and treatment of type 2 diabetes: the National Diabetes Education Program. JAMA (2000) 284:363–365.
   PubMed Web of Science ®Google Scholar
• •An excellent position paper on how the healthcare system should view the evolving epidemic of diabetes and prepare to make adaptations in meeting the public health demands of the disease from the patient and clinician perspectives.
   Google Scholar
• American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care (1998) 21:296–309.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. (1999) 131:281–303.
   PubMed Web of Science ®Google Scholar
• ••A contemporary review of the pathophysiology and medicaltreatment strategy for type 2 diabetes mellitus by a diabetes leader.
   Google Scholar
• NATIONAL DIABETES DATA GROUP: Diabetes InAmerica (2nd edition). National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication No. 95–1468 (1995).
   Google Scholar
• US DEPARTMENT OF HEALTH AND HUMAN SERVICESCFDCAP: 'National Diabetes Fact Sheet'. 1st November (1998):1–8.
   Google Scholar
• HARRIS MI, FLEGAL KM, COWIE CC et al: Prevalence ofdiabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care (1998) 21:518–524.
   Google Scholar
• KING H, AUBERT RE, HERMAN WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care (1998) 21:1414–1431.
   PubMed Web of Science ®Google Scholar
• KOPELMAN PG, HITMAN GA: Diabetes. Exploding Type II. Lancet (1998) 352:5IV5.
   Google Scholar
• AMOS AF, MCCARTY DJ, ZIMMET P: The rising global burden of diabetes and its complications: estimates and projections by 2010. Diab. Med. (1997) 1 4 (Suppl. 5):S5–S85.
   Google Scholar
• HAFFNER SM, LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl. J. Med. (1998) 339:229–234.
   PubMed Web of Science ®Google Scholar
• ••This paper provides extremely important data on how weshould position the issue of cardiovascular risk in patients with type 2 diabetes and brings to light a perspective that is useful both clinically and from a policy point of view.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care (2001) 24:S28–S32.
   Google Scholar
• ••Useful summary and updated reference on how the findingsfrom the UKPDS can be interpreted for clinical decision-making.
   Google Scholar
• FLEMING A: FDA approach to the regulation of drugs for diabetes. Am. Heart. J (1999) 138:S338–S345.
   PubMed Web of Science ®Google Scholar
• PSATY BM, WEISS NS, FURBERG CD et al.: Surrogate end points, health outcomes and the drug-approval process for the treatment of risk factors for cardiovas-cular disease. JAMA (1999) 282:786–790.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 15:318–368.
   PubMed Web of Science ®Google Scholar
• •A useful summary of the pathophysiology of type 2 diabetes.
   Google Scholar
• WITHERS DJ, WHITE M: Perspective: the insulin signaling system - a common link in the pathogenesis of type 2 diabetes. Endocrinology (2000) 141 :1917-1921.
   Google Scholar
• •Brings new observations on insulin signalling to the forefront of understanding the various pathogenesis of diabetic hyperglycaemia and insulin resistance.
   Google Scholar
• CONSOLI A: Role of liver in pathophysiology of NIDDM. Diabetes Care (1992) 15:430–441.
   PubMed Web of Science ®Google Scholar
• •Though nearly a decade old, this paper classically delineates hepatic dysfunction contributing to diabetic hyperglycaemia.
   Google Scholar
• EDELMAN SV: Type II diabetes mellitus. Adv. Intern. Med. (1998) 43:449–500.
   PubMedGoogle Scholar
• VAAG A: On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights. Dan. Med. Bull. (1999) 46:197–234.
   PubMed Web of Science ®Google Scholar
• •A comprehensive current review of type 2 diabetes mellitus with 554 references.
   Google Scholar
• LEFEBVRE PJ, SCHEEN AJ: Glucose metabolism and the postprandial state. Eur.J. Clin. Invest. (1999) 29:1–6.
   PubMed Web of Science ®Google Scholar
• TAPPY L: Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus. Diabetes Metab. (1995) 21:233–240.
   Web of Science ®Google Scholar
• RIZZA R: The role of splanchnic glucose appearance indetermining carbohydrate tolerance. Diabetes Med. (1996) 13:S23–S27.
   PubMed Web of Science ®Google Scholar
• EKBERG K, LANDAU BR, WAJNGOT A et al.: Contribu-tions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes (1999) 48:292–298.
   PubMed Web of Science ®Google Scholar
• PREVIS SF, CLINE GW, SHULMAN GI: A critical evaluationof mass isotopomer distribution analysis of gluconeo-genesis in viva Am.J. Physiol. (1999) 277:E154–E160.
   Google Scholar
• PREVIS SF, HALLOWELL PT, NEIMANIS KD, DAVID F,BRUNENGRABER H: Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis. Heterogeneity of glucose labeling in incubated hepatocytes. J Biol. Chem. (1998) 273:16853–16859.
   Google Scholar
• ADZIUK J, LEE WP: Measurement of gluconeogenesisand mass isotopomer analysis based on [U-(13)C]glucose. Am. J Physic]. (1999) 277 :E199–E207.
   Web of Science ®Google Scholar
• •A critical review of the theory and practice of mass isotopomer determination of gluconeogenesis in vivo.
   Google Scholar
• ELLEHER JK: Estimating gluconeogenesis with[U-13C]glucose: molecular condensation requires a molecular approach. Am. J. Physiol. (1 9 9 9) 277 :E395–E400.
   Google Scholar
• RODEN M: NMR and stable isotope techniques forstudies of liver metabolism in man. Horm. Metab. Res. (1997) 29:340–343.
   PubMed Web of Science ®Google Scholar
• •A concise review of in vivo 13C NMR spectroscopy-based hepatic glycogen metabolism techniques.
   Google Scholar
• BLOCH G, VELHO G: Metabolic investigations in humans by in vivo nuclear magnetic resonance. Recommendations of ALFEDIAM (French language Association for the Study of Diabetes and Metabolic Diseases). Diabetes. Metab. (1997) 23:343–350.
   Web of Science ®Google Scholar
• BARRETT EJ, LIU Z: Hepatic glucose metabolism and insulin resistance in NIDDMand obesity. BailBeres Chn. Endocrinol. Metab. (1993) 7:875–901.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the literature through 1992 on the role ofglycogenolysis in hepatic glucose output in diabetes.
   Google Scholar
• GASTALDELLI A, BALDI S, PETTITI M et al.: Influence ofobesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes (2000) 49:1367–1373.
   PubMed Web of Science ®Google Scholar
• LANDAU BR, WAHREN J, CHANDRAMOULI V, SCHUMANN WC, EKBERG K, KALHAN SC: Contributions of gluconeogenesis to glucose production in the fasted state. J. Chn. Invest. (1996) 98:378–385.
   PubMed Web of Science ®Google Scholar
• ROTHMAN DL, MAGNUSSON I, KATZ LD, SHULMAN RG,SHULMAN GI: Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science (1991) 254:573–576.
   PubMed Web of Science ®Google Scholar
• MAGNUSSON I, ROTHMAN DL, KATZ LD, SHULMAN RG,SHULMAN GI: Increased rate of gluconeogenesis in Type II diabetes mellitus. A 13C nuclear magnetic resonance study. J. Clin. Invest. (1992) 90:1323–1327.
   Google Scholar
• HELLERSTEIN MK, NEESE RA, LINFOOT P, CHRISTIANSEN M, TURNER S, LETSCHER A: Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study. J. Clin. Invest. (1997) 100:1305–1319.
   PubMed Web of Science ®Google Scholar
• PIMENTA W, NURJHAN N, JANSSON PA, STUMVOLL, M,GERICH J, KORYTKOWSKI M: Glycogen: its mode of formation and contribution to hepatic glucose output in postabsorptive humans. Diabetologia (1994) 37:697–702.
   PubMed Web of Science ®Google Scholar
• TAYEK JA, KATZ J: Glucose production, recycling andgluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study. Am. J. Physiol. (1996) 270 :E709–E717.
   PubMed Web of Science ®Google Scholar
• DIRAISON F, LARGE V, BRUNENGRABER H, BEYLOT M:Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeo-genesis and hepatic fatty acid oxidation in NIDDM. Diabetologia (1998) 41:212–220.
   Google Scholar
• •Stable isotope analysis study indicating that gluconeo-genesis is not the major contributor to hepatic glucose production in patients with type 2 diabetes mellitus.
   Google Scholar
• VAN DEN BERGHE G: The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J. Inherit. Metab. Dis. (1991) 14:407–420.
   PubMed Web of Science ®Google Scholar
• NEWGARD CB, HWANG PK, FLETTERICK RJ: The family of glycogen phosphorylases: structure and function. Crit. Rev. Biochem. Mot. Biol. (1989) 24:69–99.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review with 158 references of phosphory-lase structure and function from the authors who first cloned human liver glycogen phosphorylase.
   Google Scholar
• SPRANG SR, GOLDSMITH EJ, FLETTERICK RJ, WITHERS SG, MADSEN NB: Catalytic site of glycogen phosphorylase: structure of the T state and specificity for a-D-glucose. Biochemistry (1982) 21:5364–5371.
   PubMed Web of Science ®Google Scholar
• MARTIN JL, VELURAJA K, ROSS K et al.: Glucose analoginhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry (1991) 30:10101–10116.
   PubMed Web of Science ®Google Scholar
• WATSON KA, MITCHELL EP, JOHNSON LN et al.: Design of Inhibitors of Glycogen Phosphorylase: A Study of a-and 0-C-Glucosides and 1 -Thio-O-D-glucose Compounds. Biochemistry (1994) 33:5745–5758.
   PubMed Web of Science ®Google Scholar
• ••A key reference on the design, synthesis, structure-activityrelationships and crystallographically-determined binding of glucose analogue inhibitors.
   Google Scholar
• WATSON KA, MITCHELL EP, JOHNSON LN: Glucose analog inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. Acta. Ciystallogr. Sect. D: Biol. Ciystallogr. (1995) D51:458–472.
   Google Scholar
• GREGORIOU M, NOBLE MEM, WATSON KA et al: Thestructure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8.ANG. resolution and 100 K: the role of the water structure and its contribu-tion to binding. Protein Sci. (1998) 7:915–927.
   Google Scholar
• OSZ E, SOMSAK L, SZILAGYI L et al: Efficient inhibitionof muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spirothiohydantoin. Bioorg. Med. Chem. Lett. (1999) 9:1385–1390.
   PubMedGoogle Scholar
• MITCHELL EP, WITHERS SG, ERMERT P et al.: Ternarycomplex crystal structures of glycogen phosphorylase with the transition state analog nojirimycin tetrazole and phosphate in the T and R states. Biochemistry (1996) 35:7341–7355.
   PubMed Web of Science ®Google Scholar
• ASANO N, NASH RJ, MOLYNEUX RJ, FLEET GWJ: Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron: Asymmetry (2 0 0 0) 1 1 :1645-1680.
   Google Scholar
• WAAGEPETERSEN HS, WESTERGAARD N, SCHOUSBOE A:The effects of isofagomine, a potent glycogen phosphorylase inhibitor, on glycogen metabolism in cultured mouse cortical astrocytes. Neurochem. Int. (2000) 36:435–440.
   PubMed Web of Science ®Google Scholar
• LUNDGREN K, RASSOV A, BOLS M: NN42-1007 is a novelpotent inhibitor of hepatic glycogen phosphorylase and of hepatocyte glycogenolysis. Diabetes (1996) 45:521.
   Web of Science ®Google Scholar
• FOSGERAU K, WESTERGAARD N, QUISTORFF B, GRUNNET N, KRISTIANSEN, M, LUNDGREN, K: Kinetic andfunctionalcharacterizationof1,4-dideoxy-1,4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglycaemic effect in ob/ob mice. Arch. Biochem. Biophys. (2000) 380:274–284.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of antidiabetic potential in a non-indoleglycogen phosphorylase inhibitor.
   Google Scholar
• SHIOTA M, JACKSON PA, BISCHOFF H etal.: Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs. Am. J. Physic). (1997) 273:E868–E879.
   Google Scholar
• ••First demonstration of quantitative importance of glycogen-olysis to hepatic glucose production in a non-rodent efficacy model.
   Google Scholar
• BERGANS N, STALMANS W, GOLDMANN S, VANSTAPEL F: Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401; Inhibition and inactivation of glycogen phosphory-lase by an activated metabolite. Diabetes (2000) 49:1419–1426.
   PubMed Web of Science ®Google Scholar
• •Elegant detailed demonstration of the inter-regulation of glycogen synthesis and degradation as studied with the AMP-site GPI BAY R3401.
   Google Scholar
• ZOGRAPHOS SE, OIKONOMAKOS NG, TSITSANOU KE etal: The structure of glycogen phosphorylase bwith an alkyl-dihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure (1997) 5:1413–1425.
   PubMed Web of Science ®Google Scholar
• OIKONOMAKOS NG, TSITSANOU KE, ZOGRAPHOS SE, SKAMNAKI VT, GOLDMANN S, BISCHOFF H: Mlosteric inhibition of glycogen phosphorylase a by the potentialan tidiabeticdrug 3-isopropyl4 -(2 -chlor o ph eny1)-1, 4 -dihy dr o -1 -ethy1-2 -m ethyl-p yr idin e-3, 5, 6 -tr icar bo x ylate . Protein. Sci. (1999) 8:1930–1945.
   PubMed Web of Science ®Google Scholar
• OIKONOMAKOS NG, SCHNIER JB, ZOGRAPHOS SE, SKAMNAKI VT, TSITSANOU, KE, JOHNSON LN: Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J Biol. Chem. (2000) 275:34566–34573.
   PubMed Web of Science ®Google Scholar
• •Recent discussion of enzyme-inhibitor interactions at the purine nucleoside inhibitor (caffeine) binding site with leading references.
   Google Scholar
• SPRANG S, FLETTERICK R, STERN M, YANG D, MADSEN N, STURTEVANT J: Analysis of an allosteric binding site: the nucleoside inhibitor site of phosphorylase alpha. Biochemistry (1982) 21:2036–2048.
   PubMed Web of Science ®Google Scholar
• •Seminal description of the purine nucleoside inhibitor (caffeine) binding site.
   Google Scholar
• KLINOV SV, KURGANOV BI: Specificity of inhibition ofmuscle glycogen phosphorylase f3 by flavins. Biochem. Mol. Biol. Int. (1995) 35:643–650.
   PubMedGoogle Scholar
• KASVINSKY PJ, SHECHOSKY S, FLETTERICK RJ:Synergistic regulation of phosphorylase a by glucose and caffeine. J Biol. Chem. (1978) 253:9102–9106.
   PubMed Web of Science ®Google Scholar
• •Determination of the basis of synergy between catalytic and purine nucleoside inhibitor site ligands from kinetic data of rabbit liver and muscle phosphorylase with reference to the crystal structure of the rabbit muscle enzyme.
   Google Scholar
• ERCAN-FANG N, NUTTALL FQ: The effect of caffeine andcaffeine analogs on rat liver phosphorylase a activity. Pharmacol Exp. Ther. (1997) 280:1312–1318.
   PubMed Web of Science ®Google Scholar
• ERCAN-FANG, NG, NUTTALL FQ, GANNON MC: Uric acidinhibits liver phosphorylase a activity under simulated in vivo conditions. J. Physiol. Endocrinol. Metab. (2001) 280:E248–E253.
   PubMed Web of Science ®Google Scholar
• MARTIN WH, HOOVER DJ, ARMENTO SJ et al: Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. ScL USA. (1998) 95:1776–1781.
   PubMed Web of Science ®Google Scholar
• ••Identification of the glycogen phosphorylase inhibitoryactivity of compound 13 (CP-91,149) including characterisa-tion of acute hypoglycaemic activity in the ob/ob mouse.
   Google Scholar
• HOOVER DJ, LEFKOWITZ-SNOW S, BURGESS-HENRY JL et Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. (1998) 41:2934–2938.
   PubMed Web of Science ®Google Scholar
• ••Description of the chemical synthesis, structure-activityrelationships and biological characterisation of analogues of compounds 13 (CP-91,149) and 14 (CP-320,626).
   Google Scholar
• OIKONOMAKOS NG, SKAMNAKI VT, TSITSANOU KE, GAVALAS NG, JOHNSON LN: A new allosteric site in glycogen phosphorylase b as a target for drug interac-tions. Structure (London) (2000) 8:575–584.
   PubMed Web of Science ®Google Scholar
• •Characterisation of the binding site of compound 14 (CP-320,626) in rabbit muscle glycogen phosphorylase b.
   Google Scholar
• RATH VL, AMMIRATI M, DANLEY DE et al: Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. (2000) 7:677–682.
   PubMed Web of Science ®Google Scholar
• ••Characterisation of the indole inhibitor binding site (viacompound 15) in recombinant human liver glycogen phosphorylase a and design of a novel inhibitor (16) from this x-ray data.
   Google Scholar
• DONG W, JESPERSEN T, BOLS M, SKRYDSTRUP T, SIERKSMR: Evaluation of Isofagomine and Its Derivatives As Potent Glycosidase Inhibitors. Biochemistry (1996) 35:2788–2795.
   PubMed Web of Science ®Google Scholar
• ANDERSEN B, RASSOV A, WESTERGAARD N, LUNDGRENK: Inhibition of glycogenolysis in primary rat hepato-cytes by 1,4-dideoxy-1,4-imino-D-arabinitol. Biochem. J (1999) 342:545–550.
   PubMed Web of Science ®Google Scholar
• BOARD M, BOLLEN M, STALMANS W, YONG K, FLEET GWJ, JOHNSON LN: Effects of C-1-substituted glucose analog on the activation states of glycogen synthase and glycogen phosphorylase in rat hepatocytes. Biochem. J. (1995) 311:845–852.
   PubMed Web of Science ®Google Scholar
• MASSILLON D, BOLLEN M, DE WULF H et al: Demonstra-tion of a glycogen/glucose 1-phosphate cycle in hepatocytes from fasted rats. Selective inactivation of phosphorylase by 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride. J. Biol. Chem. (1995) 270:19351–19356.
   Google Scholar
• SOMSAK L, NAGY V, DOCSA T, TOTH B, GERGELY P: Gram-scale synthesis of a glucopyranosylidene-spiro-thiohydantoin and its effect on hepatic glycogen metabolism studied in vitro and in vivo. Tetrahedron: Asymmetry (2000) 11:405–408.
   Web of Science ®Google Scholar
• KASVINSKY PJ, FLETTERICK RJ, MADSEN NB: Regulation of the dephosphorylation of glycogen phosphorylase a and synthase b by glucose and caffeine in isolated hepatocytes. Can. J. Biochem. (1981) 59:387–395.
   PubMedGoogle Scholar
• ARMSTRONG CG, DOHERTY MJ, COHEN PT: Identifica-tion of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem. J (1998) 336:699–704.
   PubMed Web of Science ®Google Scholar
• •Informative paper linking the allosteric inhibition of protein phosphatase 1 by glycogen phosphorylase a to specific binding with the glycogen targeting subunit.
   Google Scholar
• BOLLEN M, KEPPENS S, STALMANS W: Specific features of glycogen metabolism in the liver. Biochem. J (1998) 336:19–31.
   PubMed Web of Science ®Google Scholar
• ••An excellent current review on the biochemical regulationof hepatic glycogen metabolism.
   Google Scholar
• HANSON RL, HO RS, WISEBERG JJ, SIMPSON R, YOUNATHAN ES, BLAIR JB: Inhibition of gluconeo-genesis and glycogenolysis by 2,5-anhydro-D-mannitol. J Biol. Chem. (1984) 259:218–223.
   PubMed Web of Science ®Google Scholar
• TREADWAY JL, MCPHERSON RK, GENEREUX PE et al.: The human liver glycogen phosphorylase inhibitor CP-320,626 shows sustained glucose lowering on multiple dosing in diabetic ob/ob mice. Diabetes (1998) 47 (Suppl. 0 :1115.
   Google Scholar
• •Demonstration of the multiple dose antidiabetic efficacy of compound 14 (CP-320626) in a preclinical model of human diabetes.
   Google Scholar
• KING LM, OPIE LH: Glucose and glycogen utilisation in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol. Cell.Biochem. (1998) 180:3–26.
   PubMed Web of Science ®Google Scholar
• •A good review of the relationship between carbohydrate metabolism and cardiac function in normal and pathophysiological states.
   Google Scholar
• TREADWAY JL, MAGEE WP, HOOVER DJ et al.: Cardio-protective effect of the glycogen phosphorylase inhibitor CP-380867. Diabetes (2000) 49 (Suppl. 0:517
   Google Scholar
• LAVANCHY N, GRABLY S, GARNIER A, ROSSI A: Crucial role of intracellular effectors on glycogenolysis in the isolated rat heart: potential consequences on the myocardial tolerance to ischemia. Mol. Cell. Biochem. (1996) 160–161:273–282.
   Google Scholar
• MINATOGUCHI S, ARAI M, UNO Y et al.: A novelanti-diabetic drug, miglitol, markedly reduces myocar-dial infarct size in rabbits. Br. J. Pharmacol (1999) 128:1667–1672.
   PubMed Web of Science ®Google Scholar
• •This elegant study demonstrates that the glycogen debranching enzyme inhibitor miglitol provides cardiopro-tection in vivo.
   Google Scholar
• CARSON M: Ribbons 2.0. J. Appl. Clystallog. (1991)24:958–961.
   Google Scholar
• RATH VL, AMMIRATI M, LEMOTTE PK et al.: Activation ofhuman liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol. Cell (2000) 6:139–148.
   PubMed Web of Science ®Google Scholar
• NOVO NORDISK AV: W09709040A1 (1997).
   Google Scholar
• NOVO NORDISK AV: W09524391A1 (1995).
   Google Scholar
• NOVO NORDISK AV: W09850359A1 (1998).
   Google Scholar
• NOVO NORDISK: U55863903 (1999).
   Google Scholar
• BAYER AKTIENGESELLSCHAFT: U55026714 (1991).
   Google Scholar
• BAYER AKTIENGESELLSCHAFT: U54894378 (1990).
   Google Scholar
• BAYER AKTIENGESELLSCHAFT: US4786641 (1988).
   Google Scholar
• PFIZER PRODUCTS INC: EP978279A1 (February 9, 2000).
   Google Scholar
• PFIZER INC: U5595322 (1999).
   Google Scholar